Charles River Laboratories to Acquire Rockville’s Vigene Biosciences to Enhance Gene Therapy Capabilities

Published on :

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Vigene Biosciences, Inc., a premier, U.S.-based gene therapy contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions.